December 11 2006  


 

Nucletron Sponsors the International Conference on the Optimal Use of Advanced Radiotherapy in Multimodality Oncology


Nucletron B.V., a knowledge-based leader in Radiation Oncology, is proud to announce its support for the 12th International Conference, the latest in a series intended to improve patient care throughout the world. This educational and scientific event will take place in Rome, Italy, from 20 to 23 June 2007.  


Professor Didier Peiffert from the Centre Alexis Vautrin in Nancy, France and Professor Phillip Devlin, from Harvard Medical School, Boston, MA, USA, chairpersons of the Scientific Committee preparing the conference program wrote in their invitation: “We intend to review current and evolving benefits of different radiation therapy modalities. We aim to discuss how to maximize their utilization in multimodal oncology by presenting viewpoints from various disciplines and countries and by providing new tools for improving your practice. Also, we want to offer you the opportunity to participate in networking sessions together with leading international experts.”


Participants are also invited to submit abstracts for oral or poster presentations to be held at the conference.  Abstracts will be scored and prizes awarded, based on criteria as determined by the Scientific Committee.


Conference details, abstract submission requirements, and registration information can be found by visiting the official website at http://www.rome2007.org/.


Nucletron’s mission is to work with clinical teams to realize innovative solutions that improve patient care.  It is with this core belief in mind that Nucletron is pleased to sponsor this important international conference.


About Nucletron B.V.

Nucletron is a knowledge-based leader in Radiation Oncology, working with the clinical team to realize innovative solutions that improve patient care.


We strive to offer the best possible choice of treatment modality for the patient through our integrated products, software and services. We develop cancer treatment with optimal outcomes and minimal side-effects and we promote clinical acceptance of our solutions.


For more information on Nucletron, please visit the website at www.nucletron.com.



Nucletron B.V. is a subsidiary of Delft Instruments. Delft Instruments is the holding company of an international group of companies that hold a leading position in their respective markets with high quality, high-technology products and services.  The Delft Instruments’ companies develop, produce, sell and service advanced (precision) hardware and software for medical and industrial customers. Medical applications include radiation treatment for cancer and ultrasound diagnostics. Industrial applications include measurement and control instrumentation for the storage and transport of oil and gas products. Delft Instruments employs some 1,100 people and reported turnover of EUR 243 million in 2005.


For more information on Delft Instruments, please visit the website at http://www.delftinstruments.com/.